Biologically Active Small Molecules

A typical antipsychotic that acts as an antagonist at dopamine D2 receptors (Ki = 0.38 nM) and an inverse agonist at serotonin 5-HT2A receptors (Ki = 7 nM).

Double bond isomer of trans-resveratrol, the more often studied and naturally abundant of the two resveratrol isomers exhibits antioxidant activity in the micromolar range similar to that observed with trans-resveratrol.

Double bond isomer of trans-resveratrol, the more often studied and naturally abundant of the two resveratrol isomers exhibits antioxidant activity in the micromolar range similar to that observed with trans-resveratrol.

Double bond isomer of trans-resveratrol, the more often studied and naturally abundant of the two resveratrol isomers exhibits antioxidant activity in the micromolar range similar to that observed with trans-resveratrol.

Double bond isomer of trans-resveratrol, the more often studied and naturally abundant of the two resveratrol isomers exhibits antioxidant activity in the micromolar range similar to that observed with trans-resveratrol.

A potent anti-mitotic drug that is 100-fold more active than resveratrol at inhibiting the growth of human colon cancer Caco-2 cells inhibits tubulin polymerization in a dose-dependent manner (IC₅₀ = 4 &muM) and enzymes involved in the

A potent anti-mitotic drug that is 100-fold more active than resveratrol at inhibiting the growth of human colon cancer Caco-2 cells inhibits tubulin polymerization in a dose-dependent manner (IC₅₀ = 4 &muM) and enzymes involved in the

A potent anti-mitotic drug that is 100-fold more active than resveratrol at inhibiting the growth of human colon cancer Caco-2 cells inhibits tubulin polymerization in a dose-dependent manner (IC₅₀ = 4 &muM) and enzymes involved in the

A potent anti-mitotic drug that is 100-fold more active than resveratrol at inhibiting the growth of human colon cancer Caco-2 cells inhibits tubulin polymerization in a dose-dependent manner (IC₅₀ = 4 &muM) and enzymes involved in the

A platinum-containing compound that acts as an alkylating agent used alone or in combination therapy in the treatment of several types of cancer inhibits the RecA recombinase of M. tuberculosis (IC₅₀ = 2 &microM), blocking protein

A platinum-containing compound that acts as an alkylating agent used alone or in combination therapy in the treatment of several types of cancer inhibits the RecA recombinase of M. tuberculosis (IC₅₀ = 2 &microM), blocking protein

A platinum-containing compound that acts as an alkylating agent used alone or in combination therapy in the treatment of several types of cancer inhibits the RecA recombinase of M. tuberculosis (IC₅₀ = 2 &microM), blocking protein